Journal
INTERNAL MEDICINE JOURNAL
Volume 47, Issue 1, Pages 112-115Publisher
WILEY-BLACKWELL
DOI: 10.1111/imj.13308
Keywords
idiopathic inflammatory myopathy; intravenous immunoglobulin; dermatomyositis; polymyositis; inclusion body myositis
Categories
Ask authors/readers for more resources
In South Australia, between 2000 and 2014, 57 patients with idiopathic inflammatory myositis (IIM) were treated with intravenous immunoglobulin (IVIg). We reviewed disease characteristics to determine predictors of response to therapy and IVIg dosing and duration to identify opportunities to rationalise IVIg use. Patients with dermatomyositis/polymyositis had a response rate of 77% and were more likely than inclusion body myositis to respond to therapy. Consideration should be given to the use of the lowest possible dose of IVIg and to the undertaking of trials of cessation of IVIg in patients with stable IIM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available